Piper Jaffray Companies reissued their overweight rating on shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) in a report released on Thursday. They currently have a $5.00 price target on the biotechnology company’s stock.

Several other research analysts have also weighed in on GNCA. Zacks Investment Research lowered shares of Genocea Biosciences from a hold rating to a sell rating in a report on Friday, August 11th. ValuEngine lowered shares of Genocea Biosciences from a sell rating to a strong sell rating in a report on Tuesday, September 26th. Cowen and Company reiterated a buy rating and set a $10.00 price objective on shares of Genocea Biosciences in a report on Tuesday, September 26th. Needham & Company LLC lowered shares of Genocea Biosciences from a buy rating to a hold rating in a report on Tuesday, September 26th. Finally, Stifel Nicolaus lowered shares of Genocea Biosciences from a buy rating to a hold rating and cut their price objective for the stock from $15.00 to $2.50 in a report on Monday, September 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. The company currently has an average rating of Buy and an average target price of $7.62.

Shares of Genocea Biosciences (GNCA) traded down $0.05 on Thursday, reaching $1.05. 860,382 shares of the company’s stock traded hands, compared to its average volume of 900,278. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.97 and a quick ratio of 2.97.

Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.08). During the same period last year, the firm posted ($0.45) EPS. equities research analysts anticipate that Genocea Biosciences will post -1.9 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Genocea Biosciences’ (GNCA) Overweight Rating Reaffirmed at Piper Jaffray Companies” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/genocea-biosciences-gnca-overweight-rating-reaffirmed-at-piper-jaffray-companies/1678862.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of GNCA. State Street Corp raised its holdings in Genocea Biosciences by 1,595.2% in the second quarter. State Street Corp now owns 366,172 shares of the biotechnology company’s stock valued at $1,912,000 after buying an additional 344,572 shares during the period. Northern Trust Corp raised its holdings in Genocea Biosciences by 642.9% in the second quarter. Northern Trust Corp now owns 306,597 shares of the biotechnology company’s stock valued at $1,601,000 after buying an additional 265,328 shares during the period. Northpointe Capital LLC raised its holdings in Genocea Biosciences by 9.6% in the second quarter. Northpointe Capital LLC now owns 1,336,062 shares of the biotechnology company’s stock valued at $6,974,000 after buying an additional 117,374 shares during the period. Vanguard Group Inc. raised its holdings in Genocea Biosciences by 13.9% in the second quarter. Vanguard Group Inc. now owns 856,762 shares of the biotechnology company’s stock valued at $4,472,000 after buying an additional 104,790 shares during the period. Finally, TIAA CREF Investment Management LLC purchased a new position in Genocea Biosciences in the second quarter valued at approximately $404,000. Hedge funds and other institutional investors own 57.39% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Analyst Recommendations for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.